← Evidence map

ArticleBlood2026

Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176. | OpenQuestion